Moderna closed Friday up ~14% at $225, a four-year high, after the New York Times reported new details of a planned NIH-backed public-private initiative to accelerate therapeutic cancer vaccines, expected to launch in December with ~$200M. Moderna also rejoined the Nasdaq-100 before Friday's open. Bank of America raised its target to $200 from $170 (Neutral). Vaccine peers NVAX (+16%) and BNTX (+5%) rode the same news Friday.
Useful?